Digitala Vetenskapliga Arkivet

Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Cancerprecisionsmedicin.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Cancerprecisionsmedicin. Ridgeview Instruments AB, SE-752 38, Uppsala, Sweden.ORCID-id: 0000-0002-0063-3233
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Cancerprecisionsmedicin.ORCID-id: 0000-0002-7364-5470
Vise andre og tillknytning
2023 (engelsk)Inngår i: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089Artikkel i tidsskrift (Fagfellevurdert) Epub ahead of print
Abstract [en]

Purpose

Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [177Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53 is a key player in the proapoptotic signalling in response to radiation-induced DNA damage and is therefore a potential target for radiosensitisation.

Methods

This study investigated the use of the p53 stabilising peptide VIP116 and [177Lu]Lu-DOTATATE, either alone or in combination, for treatment of neuroblastoma tumour xenografts in mice. Initially, the uptake of [177Lu]Lu-DOTATATE in the tumours was confirmed, and the efficacy of VIP116 as a monotherapy was evaluated. Subsequently, mice with neuroblastoma tumour xenografts were treated with placebo, VIP116, [177Lu]Lu-DOTATATE or a combination of both agents.

Results

The results demonstrated that monotherapy with either VIP116 or [177Lu]Lu-DOTATATE significantly prolonged median survival compared to the placebo group (90 and 96.5 days vs. 50.5 days, respectively). Notably, the combination treatment further improved median survival to over 120 days. Furthermore, the combination group exhibited the highest percentage of complete remission, corresponding to a twofold increase compared to the placebo group. Importantly, none of the treatments induced significant nephrotoxicity. Additionally, the therapies affected various molecular targets involved in critical processes such as apoptosis, hypoxia and angiogenesis.

Conclusion

In conclusion, the combination of VIP116 and [177Lu]Lu-DOTATATE presents a promising novel treatment approach for neuroblastoma. These findings hold potential to advance research efforts towards a potential cure for this vulnerable patient population.

sted, utgiver, år, opplag, sider
Springer, 2023.
Emneord [en]
Neuroblastoma, Molecular radiotherapy, p53, [177Lu]Lu-DOTATATE, Radiosensitisation
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-517191DOI: 10.1007/s00259-023-06462-3ISI: 001085247400001PubMedID: 37823909OAI: oai:DiVA.org:uu-517191DiVA, id: diva2:1817031
Forskningsfinansiär
Swedish Childhood Cancer Foundation, PR2020-0023Swedish Research Council, 2020-01377Swedish Cancer Society, CAN 20 0191Swedish Cancer Society, 2018/494Uppsala UniversitySwedish Childhood Cancer Foundation, TJ2021-0072Ulf Lundahls minnesfond
Merknad

De två första författarna delar förstaförfattarskapet

Tilgjengelig fra: 2023-12-05 Laget: 2023-12-05 Sist oppdatert: 2024-12-06bibliografisk kontrollert
Inngår i avhandling
1.
Posten ble ikke funnet. Det kan skyldes at posten ikke lenger er tilgjengelig eller det er feil id i adressefeltet.

Open Access i DiVA

fulltext(1437 kB)92 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1437 kBChecksum SHA-512
9490e926877360695eccee19abaeb0274acf8772a0697cdeb31d7b3d9ac12a8cd64eaa79efa58281a32ce09e22e1d90599678a0092e6ccdb77733575138c7399
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Berglund, HannaLundsten Salomonsson, SaraMohajershojai, TabassomLane, David P.Nestor, Marika
Av organisasjonen
I samme tidsskrift
European Journal of Nuclear Medicine and Molecular Imaging

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 92 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 96 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf